Lead discovery for unmet target-variants

We can model and scan new targets (protein genotypes) with ligand-based and structure-based drug discovery strategies. Ligand-based strategy assumes the hypothesis that similar molecules are likely to share functionality. Our platform allows a target-fit library enrichment using 2D-QSAR, Docking and hybrid Docking/QSAR strategies that can be later be refined and experimentally validated to identify new lead candidates.